Medpace Holdings, Inc. (MEDP) Cash Flow Statement

The consistent OCF/NI ratio above 1.0, peaking at 2.22x in Q3 2025, suggests that reported net income is backed by strong cash generation, not just accounting accruals. Working capital changes have been a net positive contributor in most quarters, particularly in Q3 2025 and Q4 2024, which may reflect favorable timing of client billings and collections. This conversion quality supports the reliability of earnings, though investors should monitor whether the recent EPS miss signals any deterioration in this trend.

The FCF margin trajectory has been uneven, with a peak of 39.8% in Q3 2025 driven by a large working capital inflow, followed by a decline to 19.5% in Q2 2026. This volatility appears tied to the timing of project milestones and client payments rather than operational deterioration, as FCF remains well above net income in most periods. The deceleration in revenue growth, however, suggests that FCF growth may moderate in coming quarters, warranting close monitoring of backlog conversion.

CapEx/Revenue has remained consistently below 3.5%, with the highest reading in Q2 2026 at 3.4%, likely reflecting investments in technology or lab capacity. The low capital intensity is a structural advantage for Medpace, as it allows the company to return substantial cash to shareholders without compromising growth. This suggests that maintenance capex is minimal and that any incremental spending is likely growth-oriented, though the recent uptick in Q2 2026 warrants attention.

The large positive working capital changes in Q3 2025 and Q4 2024 suggest that Medpace is collecting cash from clients ahead of project costs, a common feature in percentage-of-completion accounting. However, the negative changes in Q1 2025 and Q1 2026 indicate periods where cash outflows for project expenses outpaced billings, which may reflect trial acceleration or delayed client payments. These swings are not necessarily a red flag but highlight the lumpy nature of cash flow in a project-based business, and investors should focus on the multi-quarter trend rather than any single quarter.

The buyback activity has been substantial, with $294.8M in Q2 2026 alone, following $540.9M in Q2 2025 and $371.9M in Q1 2025, indicating management's confidence in the company's intrinsic value. This aggressive repurchase program has likely contributed to the EPS growth outpacing net income growth, as noted in the income statement analysis. The absence of dividends suggests a preference for buybacks as the primary capital return mechanism, which may be accretive to shareholders if the stock is undervalued, but also concentrates risk if the share price declines.

The cumulative OCF/NI ratio of approximately 1.49x over the last ten quarters suggests that Medpace's earnings are of high quality, with cash conversion consistently ahead of reported profits. This divergence is likely driven by the company's low capital intensity and favorable working capital dynamics, which allow it to convert a higher proportion of earnings into cash. However, the recent sub-1.0 book-to-bill ratio and EPS miss may signal that this cash generation premium could narrow if revenue growth slows and working capital tailwinds fade.